Is the business good?
How good a business is OCUL?
Ocular Therapeutix, Inc. keeps −575% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−575%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +32%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 424%
R&D as % of revenue
- Gross margin
- 87%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −361% |
| FY2021 | −179% |
| FY2022 | −153% |
| FY2023 | −141% |
| FY2024 | −270% |
| FY2025 | −520% |
Details›
- Gross margin12 months to Q1 2026
- 87%
- Operating margin12 months to Q1 2026
- −575%
- Net margin12 months to Q1 2026
- −558%
- Free cash flow margin
- −463%
- R&D as % of revenue
- 424%
- Revenue, trailing twelve months
- $52M
- Free cash flow, trailing twelve months
- −$241M
- Net income, trailing twelve months
- −$290M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.